1636
The clinical course suggested that recombinant alpha-2b peginterferon plus ribavirin provoked type 1 diabetes mellitus, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment.
 type 1 diabetes mellitus: Effect; recombinant alpha-2b peginterferon plus ribavirin: Treatment; recombinant alpha-2b peginterferon: Treatment.Drug; ribavirin: Treatment.Drug; ribavirin: Combination.Drug; recombinant alpha-2b peginterferon: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 type 1 diabetes mellitus: Effect; recombinant alpha-2b peginterferon plus ribavirin: Treatment; recombinant alpha-2b peginterferon: Treatment.Drug; ribavirin: Treatment.Drug; ribavirin: Combination.Drug; recombinant alpha-2b peginterferon: Combination.Drug